Friday, May 31, 2019

NOVIS PR Recalls PECGEN DMX, 16 oz, a liquid cough syrup


NOVIS PR LLC Issues Voluntary Nationwide Recall of PECGEN DMX Due to a Labeling Error



Summary

Company Announcement Date:
May 29, 2019
FDA Publish Date:
May 30, 2019
Reason for Announcement:
Incorrect dosage on label
Company Name:
NOVIS PR LLC
Brand Name:
Pecgen DMX,
Product Description:
PECGEN DMX, 16 oz, liquid cough syrup

FDA Announcement

Novis PR LLC is voluntarily recalling 5 lots of PECGEN DMX, 16 oz, a liquid cough syrup to the consumer level. The product has been found to provide incorrect dosage information on its label due to a typographical error. The drug facts label (example below) incorrectly states children 6 to under 2 years of age, 1 teaspoonful every 4 hours, not to exceed 4 teaspoonfuls in 24 hours or directed by physician. The label should state children 6 to under 12, 1 teaspoonful every 4 hours, not to exceed 4 teaspoonfuls in 24 hours or as directed by physician. Additionally, the label does not advise consumers to consult a doctor for children under 2 years of age.
Children 6 to under 2 years of age1 teaspoonful (tsp) every 4 hours not to exceed 4 teaspoonfuls in 24 hours, or as directed by a doctor
Risk Statement: There is no evidence that cough and cold medicines are safe or effective for young children. However, there is evidence that children have been harmed by overdoses of these products. Problems include seizures, coma, and death. Dextromethorphan can also interact with Tylenol or other cough/cold medications to be highly toxic—more than if given alone. To date,  NOVIS PR LLC has not received any reports of adverse events related to this recall.
The product is used as a Cough suppressant and expectorant and is packaged in Amber plastic 16 oz bottles in cases of 12 units with NDC 52083-630-16. The affected PECGEN DMX lots include the following lot numbers and expiration dates: D80202 Exp date 02/20, D80210 Exp 02/20, D80818 Exp 09/20, D80819 Exp 09/20, D80820 Exp 09/20.
Error was discovered by an email notification of an unidentified individual alerting of incorrect information in label.
PECGEN DMX was distributed in Puerto Rico to Wholesalers and retail pharmacies. Product is only sold in Puerto Rico.
Novis PR LLC is notifying its distributors and customers by letters and phone calls the collection of the units and is arranging the return of all recalled products.
Consumers who have PECGEN DMX which is being recalled should stop using/return to place of purchase/discard/contact their doctor, etc.
Distributors/retailers that have PECGEN DMX which is being recalled should stop distributing the product and must return it to place of purchase.
Consumers with questions regarding this recall can contact Novis PR LLC at (787) 767-2072 or  info@kramernovis.com from Monday thru Friday, 7:30am – 4:30pm (AST).
Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

FDA Contact Information

Consumers:
Novis PR LLC
 (787) 767-2072
 info@kramernovis.com

Product Photos

NOVIS recogido PECGEN DMX ( NOVIS PR LLC emite recogido voluntario a nivel nacional de PECGEN DMX debido a error en etiqueta)


NOVIS PR LLC emite recogido voluntario a nivel nacional de PECGEN DMX debido a error en etiqueta




Summary

Company Announcement Date:
May 29, 2019
FDA Publish Date:
May 30, 2019
Reason for Announcement:
Incorrect dosage on label
Company Name:
NOVIS PR LLC
Brand Name:
Pecgen DMX,
Product Description:
PECGEN DMX, 16 oz, liquid cough syrup

FDA Announcement

Novis PR LLC está llevando a cabo un recogido voluntario a nivel de consumidor de 5 lotes de PECGEN DMX, 16 oz, jarabe para la tos.  La etiqueta del producto contiene un error tipográfico proveyendo dosificación incorrecta.
La etiqueta indica dosificación en niños de 2-6 años de edad, una cucharadita cada 4 horas, sin exceder 4 cucharaditas en 24 horas o según indique su médico. La dosificación correcta debe indicar niños de 6-12 años de edad, una cucharadita cada 4 horas, sin exceder 4 cucharaditas en 24 horas o según indique su médico. En adición, la etiqueta no provee recomendación a los consumidores de consultar a su médico sobre uso para niños menores de 2 años de edad.
Niños de 2-6 anos de edadUna cucharadita cada 4 horas, sin exceder 4 cucharaditas en 24 horas o según indique su médico.
Riesgos: No hay evidencia que los jarabes para el catarro sean seguros o efectivos para niños pequeños. Hay evidencia que podrían llegar a causar sobre dosis en niños pequeños. Problemas pudieran presentar convulsiones, coma y/o muerte. Dextrometorfano puede interactuar con Tylenol y otros jarabes pudiendo tener una reacción toxica.  Hasta la fecha, Novis PR LLC no ha recibido ninguna queja o evento adverso relacionado a este recogido.
El producto es utilizado como un expectorante y supresor de la tos, empacado en frascos plásticos oscuros de 16 oz.  en cajas de 12 unidades con NDC 52083-630-16.
Los lotes afectados de PECGEN DMX son D80202 Exp date 02/20, D80210 Exp date 02/20, D80818 Exp date 09/20, D80819 Exp 09/20, D80820 Exp 09/20.
El producto puede ser identificado con la siguiente etiqueta:
Error en etiqueta fue descubierto mediante alerta de email de fuente no identificada.
PECGEN DMX ha sido distribuido en Puerto Rico a nivel de droguerías y farmacias. Producto solo se vendió en Puerto Rico.
Novis PR LLC está notificando a sus clientes y distribuidores por carta y llamadas telefónicas del manejo y recogido de unidades del producto en cuestión.
Consumidores que tengan PECGEN DMX de los lotes mencionados deben cesar el uso/devolver/desechar/comunicarse al médico si necesario, etc.
Distribuidores/minoristas que tengan PECGEN DMX de los lotes mencionados deben cesar la distribución del producto y devolverlo a su origen de compra.
Consumidores con dudas referentes a este recogido pueden comunicarse con NOVIS PR LLC al (787)767-2072 o info@kramernovis.com de Lunes a Viernes. 7:30am-4:30pm (AST).
Usuarios deben comunicarse con su médico si han experimentado problemas que pudieran estar relacionados al uso de este medicamento.
Eventos adversos o de calidad experimentados al uso de este producto pueden ser reportados a FDA's MedWatch Adverse Event Reporting program por internet, correo o fax.

GA

Make sure you know about all recalls & keep your family safe, Subscribe Free via email

Enter your email address Or Click on FeedBurner Icon (Right) to subscribe via Your News Reader. Your Email is never shared:

Delivered by FeedBurner